PARP
poly ADP ribose polymerase
PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell’s nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.
PARP Isoform Specific Products
-
PARP
(302)
View all products
-
PARP1
(204)
View all products
-
PARP2
(82)
View all products
-
PARP3
(22)
View all products
-
PARP4
(11)
View all products
-
TNKS1/PARP5A
(40)
View all products
-
TNKS2/PARP5B
(37)
View all products
-
PARP7
(24)
View all products
-
PARP10
(20)
View all products
-
PARP14
(17)
View all products
-
PARP15
(14)
View all products
-
PARP12
(4)
View all products
-
PARP16
(3)
View all products
All Product Categories
-
PARP Inhibitors
(456)
View all products
-
PARP Agonists
(4)
View all products
-
PARP Activators
(104)
View all products
-
PARP Modulators
(11)
View all products
-
PARP Inducers
(20)
View all products
-
PARP Degraders
(23)
View all products
-
PARP Substrate
(1)
View all products
-
PARP Ligands
(4)
View all products
-
PARP Related Products (680)
Related Products (680)
-
Antibodies (11)
-
PARP Isoform Comparison
-
WP-1034
0 ImagesCat. No.: HY-111275CAS No.: 857064-42-7
-
BSI-001
0 ImagesCat. No.: HY-P991977Synonyms: 5G9BSI-001 (5G9) is a HER2-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of HER2-positive breast cancer and HER2-overexpressing gastric cancer.
-
ATR/PARP1-IN-1
0 ImagesCat. No.: HY-174828ATR/PARP1-IN-1 is a potent ATR and PARP1 dual inhibitor with IC50s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change.
-
GPI 15427
0 ImagesCat. No.: HY-15048CAS No.: 805242-85-7GPI 15427 is a potent inhibitor of the enzyme poly (ADP-ribose) polymerase-1 (PARP-1), which plays a harmful role during inflammation. In a rat model of gut injury and inflammation, including splanchnic artery occlusion (SAO) shock and dinitrobenzene sulfonic acid (DNBS)-induced colitis, GPI 15427 demonstrates strong anti-inflammatory effects that reduces inflammatory cell infiltration, histological injury. GPI 15427 also diminishes the accumulation of poly (ADP-ribose) in the ileum and colon of treated rats.
-
PARP1/EZH2-IN-1
0 ImagesCat. No.: HY-179386PARP1/EZH2-IN-1 is a selective PARP1 and EZH2 dual inhibitor. PARP1/EZH2-IN-1 has IC50s of 28 nM, 414 nM and 74 nM for PARP1, PARP2 and EZH2, respectively. PARP1/EZH2-IN-1 inhibits the proliferation and migration of TNBC cells (triple-negative breast Cancer cells). PARP1/EZH2-IN-1 induces PANoptosis (Apoptosis, Pyroptosis and Necroptosis), increases the level of reactive oxygen species (ROS), and activates related inflammatory pathways. PARP1/EZH2-IN-1 can be used in triple-negative breast cancer research.
-
BCL-XL-IN-5
0 ImagesCat. No.: HY-184471CAS No.: 2599098-78-7BCL-XL-IN-5 is an orally active, highly selective BH3-mimetic BCL-XL inhibitor with a cKi of 7.96 pM. BCL-XL-IN-5 triggers caspase-3 activation and robust PARP cleavage to initiate apoptosis in BCL-XL-dependent MOLT-4 T-cell acute lymphoblastic leukemia cells. BCL-XL-IN-5 serves as a potent selective probe for investigating BCL-XL-dependent malignancies, such as acute lymphoblastic leukemia.
-
PARP-1-IN-13
0 ImagesCat. No.: HY-155122CAS No.: 2999661-74-2
-
PARP1/BRD4-IN-1
0 ImagesCat. No.: HY-144338CAS No.: 2758117-74-5
-
TC-E 5001
0 ImagesCat. No.: HY-108516CAS No.: 865565-29-3TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively.
-
BYK 49187
0 ImagesCat. No.: HY-108633CAS No.: 163120-31-8AR-C66096 (FPL 66096) tetrasodium is a selective platelet P2YT receptor antagonist. AR-C66096 tetrasodium effectively blocks ADP-induced platelet aggregation. AR-C66096 tetrasodium can be used in the research of thromboembolism.
-
CU-TZD-20
0 ImagesCat. No.: HY-179091CU-TZD-20 is a PARP-1 inhibitor. CU-TZD-20 has a high affinity for binding to the PARP-1 catalytic domain and good structural stability. CU-TZD-20 competitively occupies NAD+ binding sites and forms stable interactions with key catalytic residues. CU-TZD-20 can be used for cancer research.
-
Viriditoxin
0 ImagesCat. No.: HY-126051CAS No.: 1381782-08-6Synonyms: (-)-ViriditoxinViriditoxin ((-)-Viriditoxin) is a mycotoxin. Viriditoxin promotes tubulin polymerization, and inhibits FtsZ polymerization and GTPase activity. Viriditoxin exhibits cytotoxicity against cancer cells, induces apoptosis, inhibits cell migration and colony formation, induces G2/M phase arrest, and triggers autophagic cell death. Viriditoxin activates caspase-3, cleaves PARP, promotes cytochrome c release, and induces ROS production. Viriditoxin possesses broad-spectrum antibacterial activity against Gram-positive pathogenic bacteria, fish pathogenic bacteria, and permeabilized Gram-negative bacteria. Viriditoxin can be used in research related to ovarian cancer, lung cancer, nasopharyngeal carcinoma, colon cancer, neuroblastoma, prostate cancer, leukemia, lymphoma, bacterial infections, and streptococcosis.
-
YCH3292
0 ImagesCat. No.: HY-180809CAS No.: 3049753-10-5YCH3292, a derivative of YCH189 (HY-155993) is a potent, selective and orally active PARP1/2 inhibitor with IC50 both <0.001 nM. YCH3292 can increase the stability of PARP-DNA complexes. YCH3292 exhibits robust antiproliferative activity. YCH3292 can induce double-strand breaks in DNA, increase the protein levels of γH2AX, P-RPA32, and P-Chk1 and induce tumor cells S or G2/M phase arrest and apoptosis. YCH3292 can inhibit tumor growth in MC38 xenograft model.
-
PARP-1-IN-1
0 ImagesCat. No.: HY-144642CAS No.: 2763840-83-9PARP-1-IN-1 is a high selective and orally active PARP-1 inhibitor (IC50=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model.
-
CIB-Q22
0 ImagesCat. No.: HY-184448CAS No.: 2963747-43-3CIB-Q22 is a potent pyruvate carboxylase (PC) inhibitor with an IC50 of 1.74 nM. CIB-Q22 suppresses hepatocellular carcinoma (HCC) cell proliferation, migration, and invasion. CIB-Q22 induces apoptosis and ferroptosis, promotes mitochondrial oxidative stress and dysfunction, inhibits glycolysis and anaplerotic flux, and reverses epithelial-mesenchymal transition (EMT). CIB-Q22 can be used for the study of hepatocellular carcinoma.
-
Calactin
0 ImagesCat. No.: HY-167237CAS No.: 20304-47-6Calactin is a glycoside that can be isolated from Asclepias curassavica L.. Calactin activates caspase-3, caspase-8, caspase-9, and phosphorylates ERK. Calactin induces DNA damage, apoptosis, PARP cleavage, G2/M phase cell cycle arrest, shifts Bax/Bcl-2 expression, and shows anti-proliferation effects in leukemia cells. Calactin can be used for the research of leukemia.
-
BCS12
0 ImagesBCS12 is a CAIX inhibitor. BCS12 inhibits the viability of cancer cells under hypoxic conditions. BCS12 elevates ROS levels and suppresses the expression of HIF-1α and CA9. BCS12 downregulates Bcl-2, activates caspase-9, caspase-3, caspase-7 and Bax, and induces PARP cleavage and apoptosis. BCS12 reduces tumor burden, increases the number of apoptotic nuclei and restores tissue structure in rats bearing breast tumors. BCS12 can be used in research related to triple-negative breast cancer.
-
PARP1-IN-54
0 ImagesCat. No.: HY-185143CAS No.: 2915309-47-4PARP1-IN-54 (example 5) is a PARP1 inhibitor with antitumor effects.
-
PARP1-IN-47
0 ImagesCat. No.: HY-178468CAS No.: 3053592-61-0
